CU20090007A6 - A PHARMACEUTICAL COMPOUND AND A PROCESS OF THE SAME - Google Patents
A PHARMACEUTICAL COMPOUND AND A PROCESS OF THE SAMEInfo
- Publication number
- CU20090007A6 CU20090007A6 CU20090007A CU20090007A CU20090007A6 CU 20090007 A6 CU20090007 A6 CU 20090007A6 CU 20090007 A CU20090007 A CU 20090007A CU 20090007 A CU20090007 A CU 20090007A CU 20090007 A6 CU20090007 A6 CU 20090007A6
- Authority
- CU
- Cuba
- Prior art keywords
- pharmaceutically acceptable
- immunosuppressant
- same
- pharmaceutical compound
- egfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
Se proporciona una combinación terapéutica de un agente inhibidor del EGFR que inhibe competitivamente la unión del EGF nativo a su receptor y un inmunosupresor para tratar un huésped mamífero, preferiblemente humano mediante la administración de una cantidad terapéuticamente efectiva del fármaco para la profilaxis y/o tratamiento de tumores. El Inmunosupresor seleccionado del grupo comprende la Rapamicina, el tacrolimus, everolimus, pimecrolimus en su forma libre o en la forma de una sal o solvatos farmecéuticamente aceptables. También se comtemplan los nuevos conjugados del anti-EGFR con fármacos, y las composiciones que contengan opcionalmente por lo menos un portador farmacéuticamente aceptable para uso simultáneo.A therapeutic combination of an EGFR inhibitor is provided that competitively inhibits the binding of native EGF to its receptor and an immunosuppressant to treat a mammalian host, preferably human by administering a therapeutically effective amount of the drug for prophylaxis and / or treatment. of tumors The immunosuppressant selected from the group comprises Rapamycin, tacrolimus, everolimus, pimecrolimus in its free form or in the form of a pharmaceutically acceptable salt or solvate. The new anti-EGFR conjugates are also contemplated with drugs, and compositions that optionally contain at least one pharmaceutically acceptable carrier for simultaneous use.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2373CH2007 | 2007-10-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20090007A6 true CU20090007A6 (en) | 2011-07-11 |
CU23798B6 CU23798B6 (en) | 2012-03-15 |
Family
ID=40579132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20090007A CU23798B6 (en) | 2007-10-22 | 2009-01-13 | PHARMACEUTICAL COMBINATION USING ANTIBODIES AGAINST THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND IMMUNOSUPPRESSING AGENTS |
Country Status (5)
Country | Link |
---|---|
AR (1) | AR072759A1 (en) |
CU (1) | CU23798B6 (en) |
TW (1) | TW200942260A (en) |
UY (1) | UY31417A1 (en) |
WO (1) | WO2009054001A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8481498B1 (en) | 2012-01-17 | 2013-07-09 | Steven Hoffman | Pharmaceutical compositions and methods |
US10646552B2 (en) | 2012-01-17 | 2020-05-12 | Tyme, Inc. | Pharmaceutical compositions and methods |
US10272068B2 (en) | 2012-01-17 | 2019-04-30 | Tyme, Inc. | Pharmaceutical compositions and methods |
US20130183263A1 (en) | 2012-01-17 | 2013-07-18 | Steven Hoffman | Pharmaceutical compositions and methods |
US9326962B2 (en) | 2013-10-22 | 2016-05-03 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
US9585841B2 (en) | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
US9763903B2 (en) | 2013-10-22 | 2017-09-19 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
US10751313B2 (en) | 2013-10-22 | 2020-08-25 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
US10813901B2 (en) | 2013-10-22 | 2020-10-27 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
CN100522967C (en) * | 2002-02-01 | 2009-08-05 | 阿里亚德基因治疗公司 | Phosphorus-containing compounds & uses thereof |
US20050276812A1 (en) * | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
US20050142133A1 (en) * | 2003-12-03 | 2005-06-30 | Xencor, Inc. | Optimized proteins that target the epidermal growth factor receptor |
KR101354828B1 (en) * | 2005-11-04 | 2014-02-18 | 와이어쓰 엘엘씨 | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
WO2007059782A1 (en) * | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
WO2007106503A2 (en) * | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
-
2008
- 2008-10-20 WO PCT/IN2008/000688 patent/WO2009054001A1/en active Application Filing
- 2008-10-21 TW TW097140269A patent/TW200942260A/en unknown
- 2008-10-22 AR ARP080104588A patent/AR072759A1/en unknown
- 2008-10-22 UY UY31417A patent/UY31417A1/en not_active Application Discontinuation
-
2009
- 2009-01-13 CU CU20090007A patent/CU23798B6/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CU23798B6 (en) | 2012-03-15 |
TW200942260A (en) | 2009-10-16 |
WO2009054001A1 (en) | 2009-04-30 |
UY31417A1 (en) | 2009-05-29 |
AR072759A1 (en) | 2010-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20090007A6 (en) | A PHARMACEUTICAL COMPOUND AND A PROCESS OF THE SAME | |
AR048502A1 (en) | ANTI-CANCER COMPOUND THERAPEUTIC SYNERGY | |
CO6390066A2 (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
CO6251364A2 (en) | DERIVATIVES OF MORFOLINO PIRIMIDINA USED IN DISEASES RELATED TO MTOR QUINASA AND / OR P13K | |
UY29087A1 (en) | ADAMANTILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USE | |
UY30559A1 (en) | DERIVATIVES OF MORFOLINO PIRIMIDINA, PREPARATION PROCESSES, COMPOSITIONS CONTAINING THEM AND APPLICATIONS | |
BR112016012506A8 (en) | pharmaceutical combinations, their uses, and use of a data carrier | |
AR070299A1 (en) | DERIVATIVES OF PIRAZOLOPIRIMIDINAS AS INHIBITORS OF CYCLININE DEPENDENT KINASES, USES AND PHARMACEUTICAL COMPOSITIONS | |
AR107871A1 (en) | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | |
AR090349A1 (en) | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS, KIT AND USE | |
DOP2005000039A (en) | HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE | |
AR083787A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A SODIUM-GLUCOSE TRANSPORTER 2 INHIBITOR (SGLT2) AND AN INSULIN, TREATMENT PROCEDURES AND USES OF THE SAME | |
EA200971081A1 (en) | PURINUM DERIVATIVES AND THEIR APPLICATION AS A TALL-SIMILAR RECEPTOR MODULATORS 7 | |
GT200600163A (en) | NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | |
AR096892A1 (en) | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | |
AR060019A1 (en) | PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER | |
UY28979A1 (en) | DERIVATIVES OF 3-CARBOXAMIDE HYDROCLORURES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURE AND ITS USE, USED AS SELECTED INHIBITORS OF GSK3 | |
AR083267A1 (en) | PHARMACEUTICAL COMBINATIONS | |
RU2008148597A (en) | PHARMACEUTICAL COMBINATIONS | |
CO6361995A2 (en) | ISOQUINOLINONE DERIVATIVES AS AN NG3 ANTAGONISTS | |
AR085183A1 (en) | COMPOUND 6- (1-METHYL-1H-PIRAZOL-4-IL) -3- (2-METHYL-2H-INDAZOL-5-ILTIO) - [1,2,4] TRIAZOL [4,3-B] PIRIDAZINE, PHARMACEUTICAL COMPOSITION THAT UNDERSTAND AND USE IT TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT CANCER | |
DOP2019000100A (en) | DERIVATIVES OF NAFTIRIDINONE AND ITS USE IN THE TREATMENT OF ARRITMIA | |
AR091724A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE, PHARMACEUTICAL COMPOSITION | |
RU2014137190A (en) | COMBINATIONS OF HISTON-DEACETHYLASE AND PAZOPANIBA INHIBITOR AND THEIR APPLICATION | |
UY31672A1 (en) | "MUSCARINIC RECEPTORS AGONISTS PHARMACEUTICAL COMPOSITIONS METHODS OF TREATMENT OF THE SAME, AND PROCEDURES FOR THEIR PREPARATION" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent |